Clinical Trial Update: CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating neoadjuvant CAPOX plus sintilimab and the bevacizumab biosimilar IBI305 for locally advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• CAPOX (capecitabine + oxaliplatin)
• IBI305 (bevacizumab biosimilar)
• Sintilimab (sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING